secwatch.observer — SEC 8-K summary
======================================

Issuer:     RIGEL PHARMACEUTICALS INC (RIGL)
CIK:        0001034842
Form:       8-K
Filed at:   2023-01-09T23:59:59+00:00
Accession:  0001104659-23-002074
Event type: other_material
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Rigel reports preliminary Q4 revenue ~$51.3M; launches REZLIDHIA for AML
------------------------------------------------------------------------

- Preliminary Q4 total revenue ~$51.3M including TAVALISSE $21.9M (+24% YoY) and REZLIDHIA $0.9M (launched Dec 22).
- Recognized $20M milestone from Kissei for Japan PMDA approval of TAVALISSE in chronic ITP; payment expected Q1 2023.
- Cash, equivalents and short-term investments ~$58.2M as of Dec 31, 2022 (vs $125.0M a year earlier).
- REZLIDHIA (olutasidenib) FDA approved for R/R AML with IDH1 mutation; commercial launch underway.
- First patients dosed in Phase 1b trial of R289 (IRAK1/4 inhibitor) for lower-risk MDS.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1034842/000110465923002074/0001104659-23-002074-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1034842/000110465923002074/tm232596d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-23-002074

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer